Beneficial Cardiovascular Effects of Endothelin ET A Receptor Blockade in Established Long-Term Heart Failure After Myocardial Infarction

Abstract

Although experimental prevention studies have suggested therapeutic potential of endothelin (ET) antagonists for the treatment of heart failure, the results of clinical trials using ET antagonists on top of standard heart failure medications have been largely disappointing. This experimental study investigated the effects of chronic ET_A receptor blockade in long-term survivors of myocardial infarction who had developed stable chronic heart failure in the absence of other treatments. Systolic blood pressure, heart rate, organ weights of the right atrium and ventricle, and the lungs were determined, and tissue ET-1 peptide levels were measured in cardiac tissue, lung, and aorta. The results show that chronic blockade of ET_A receptors stabilizes systolic blood pressure and reverses the heart failure–induced weight increases of right heart chambers and lung. The changes observed occurred independently of tissue ET-1 concentrations and heart rate, suggesting mechanisms independent of local cardiac or pulmonary ET-1 synthesis, which are yet to be identified.

Get full access to this article

View all access options for this article.

References

Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 1:986–1001, 2002.

Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun 161:562–567, 1989.

Pacher R, Bergler-Klein J, Globits S, Teufelsbauer H, Schuller M, Krauter A, Ogris E, Rodler S, Wutte M, Hartter E. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 71:1293–1299, 1993.

McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 85:1374–1379, 1992.

Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102:2434–2440, 2000.

Spieker LE, Mitrovic V, Noll G, Pacher R, Schulze MR, Muntwyler J, Schalcher C, Kiowski W, Luscher TF. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 35:1745–1752, 2000.

Spieker LE, Luscher TF. Endothelin receptor antagonists in heart failure—a refutation of a bold conjecture? Eur J Heart Fail 5:415–417, 2003.

Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384:353–355, 1996.

Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96:1976–1982, 1997.

10.

Benigni A, Perico N, Remuzzi G. The potential of endothelin antagonism as a therapeutic approach. Expert Opin Investig Drugs 13:1419–1435, 2004.

11.

Pfeffer MA, Pfeffer JM, Fishbein MC, Fletcher PJ, Spadaro J, Kloner RA, Braunwald E. Myocardial infarct size and ventricular function in rats. Circ Res 44:503–512, 1979.

12.

Brandes RP, Walles T, Koddenberg G, Gwinner W, Mugge A. Endothelium-dependent vasodilatation in Spraguedawley rats with postinfarction hypertrophy: lack of endothelial dysfunction in vitro. Basic Res Cardiol 93:463–469, 1998.

13.

Barton M, Shaw S, d’Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ET_A receptors for endothelin regulation. Biochem Biophys Res Commun 238:861–865, 1997.

14.

Nguyen QT, Colombo F, Rouleau JL, Dupuis J, Calderone A.LU135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol 130:1525–1530, 2000.

15.

Traupe T, Munter K, Barton M. Impaired sodium and potassium excretion with aging is regulated by increased endothelin (abstract). Circulation 106:684, 2002.

16.

Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 282: 1312–1318, 1997.

17.

Jasmin JF, Cernacek P, Dupuis J. Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ET_A receptor blockade. Clin Sci (Lond) 105:647–653, 2003.

18.

Dupuis J, Prie S. The ET(A)-receptor antagonist LU 135252 Prevents the progression of established pulmonary hypertension induced by monocrotaline in rats. J Cardiovasc Pharmacol Ther 4:33–39, 1999.

19.

Ortmann J, Amann K, Brandes RP, Kretzler M, Münter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for the reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 44:974–981, 2004.

20.

Essalihi R, Dao HH, Gilbert LA, Bouvet C, Semerjian Y, McKee MD, Moreau P. Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase. Circulation 112:1628–1635, 2005.